Please assess the completion status of the following clinical trial:

Trial Title: A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Participants must provide documentation showing a sustained virologic response (SVR) for at least 1 year (52 weeks) prior to the date of screening (SVR is defined as a negative hepatitis C RNA greater than or equal to 12 weeks from the end of therapy)~* Participants must have METAVIR Stage 3 or 4 (or equivalent if using other classification; eg, Ishak)~Exclusion Criteria:~* Other causes of liver disease (eg, alcoholic liver disease, HBV \[serologically positive as determined using United States Centers for Disease Control and Prevention guidance for interpretation of hepatitis B serologic test results\], autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, NASH, hemochromatosis)~* Participants having liver diseases associated with infection with any other hepatitis virus~* Detectable HCV RNA at screening~* Child-Pugh score \> 6~* Model for End-Stage Liver Disease score \>12~* Evidence of HCC at screening based on alpha-fetoprotein (AFP) levels: AFP \> 100 ng/mL (\> 82.6 IU/mL) OR AFP ≥ 50 and ≤ 100 ng/mL (≥ 41.3 IU/mL and ≤ 82.6 IU/ mL) with liver ultrasound showing findings suspicious for HCC, or any imaging technique (eg, magnetic resonance imaging \[MRI\] or computed tomography; based on local assessment), or ultrasound~* Blood transfusion in the last 6 months prior to screening due to the risk of re-infection with HCV, HBV, HIV, etc~* Participant has any disease or condition which, in the opinion of the investigator, might compromise patient safety (eg, hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, central nervous system, or compliment-mediated disease); or other conditions that may interfere with the absorption, distribution, metabolism, or excretion of BMS 986263, or would place the participant at increased risk~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 BMS-986263 45mg weekly (Type: EXPERIMENTAL): None
- Part 1 BMS-986263 90mg weekly (Type: EXPERIMENTAL): None
- Part 1 Placebo weekly (Type: PLACEBO_COMPARATOR): None
- Part 2 BMS-986263 45mg every 2 weeks (Type: EXPERIMENTAL): None
- Part 2 BMS-986263 90mg every 2 weeks (Type: EXPERIMENTAL): None
- Part 2 BMS-986263 90mg every 4 weeks (Type: EXPERIMENTAL): None
- Part 2 Placebo every 2 weeks (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).